In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Integra LifeSciences shows a high-confidence fair value 17% above the current price suggesting potential undervaluation, but financial health scores reveal poor profitability and growth. Monte Carlo analysis indicates extreme valuation volatility with a wide value range and significant downside risk (17.6% below current price). Price/Sales and EV/Revenue metrics indicate substantial upside, contrasting sharply with analyst target pessimism.